EyePoint Pharmaceuticals (NASDAQ:EYPT) is up 8% premarket on modest volume in reaction to its three-year agreement with Vizient under which it will offer postoperative eye inflammation med DEXYCU (dexamethasone intraocular suspension 9%) to its membership at a discounted price.
Vizient, the integration of VHA, University HealthSystem and Novation, includes more than half of U.S. acute care providers and more than 20% of ambulatory care providers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.